Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Michele A Faulkner. (2014) Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson’s disease. Expert Opinion on Drug Safety 13:8, pages 1055-1069.
Read now
Read now
Vaibhav Gaur, Subhash L. Bodhankar, V. Mohan & Prasad A. Thakurdesai. (2013) Neurobehavioral assessment of hydroalcoholic extract of Trigonella foenum-graecum seeds in rodent models of Parkinson’s disease. Pharmaceutical Biology 51:5, pages 550-557.
Read now
Read now
Aloke K Dutta PhD & Weidong Le MD, PhD. (2006) Existing dopaminergic therapies for Parkinson’s disease. Expert Opinion on Therapeutic Patents 16:12, pages 1613-1625.
Read now
Read now
Articles from other publishers (22)
Mario F. Muñoz, Sandro Argüelles, Rafael Medina, Mercedes Cano & Antonio Ayala. (2019) Adipose‐derived stem cells decreased microglia activation and protected dopaminergic loss in rat lipopolysaccharide model. Journal of Cellular Physiology 234:8, pages 13762-13772.
Crossref
Crossref
Larry Yet. 2018. Privileged Structures in Drug Discovery. Privileged Structures in Drug Discovery
284
320
.
Larry Yet. 2018. Privileged Structures in Drug Discovery. Privileged Structures in Drug Discovery
237
283
.
Werner J. Geldenhuys, Akiko Kochi, Li Lin, Vijaykumar Sutariya, Dean E. Dluzen, Cornelis J. Van der Schyf & Mi Hee Lim. (2014) Methyl Yellow: A Potential Drug Scaffold for Parkinson's Disease. ChemBioChem 15:11, pages 1591-1598.
Crossref
Crossref
J. Nathan, Siddika Panjwani, V. Mohan, Veena Joshi & Prasad Arvind Thakurdesai. (2014)
Efficacy and Safety of Standardized Extract of
Trigonella foenum-graecum
L Seeds as an Adjuvant to L-Dopa in the Management of Patients with Parkinson's Disease
. Phytotherapy Research 28:2, pages 172-178.
Crossref
Crossref
Sandipan Bhattacharjee & Usha Sambamoorthi. (2013) Co-occurring chronic conditions and healthcare expenditures associated with Parkinson's disease: A propensity score matched analysis. Parkinsonism & Related Disorders 19:8, pages 746-750.
Crossref
Crossref
C. J. Yong-Kee, D. Salomonczyk & J. E. Nash. (2010) Development and Validation of a Screening Assay for the Evaluation of Putative Neuroprotective Agents in the Treatment of Parkinson’s Disease. Neurotoxicity Research 19:4, pages 519-526.
Crossref
Crossref
Jaime Kulisevsky & Javier Pagonabarraga. (2010) Tolerability and Safety of Ropinirole versus Other Dopamine Agonists and Levodopa in the Treatment of Parkinsonʼs Disease. Drug Safety 33:2, pages 147-161.
Crossref
Crossref
Li-Kang Zhang & Birendra N. Pramanik. (2010)
Characterization of major degradation products of an adenosine A
2A
receptor antagonist under stressed conditions by LC-MS and FT tandem MS analysis
. Journal of Mass Spectrometry 45:2, pages 146-156.
Crossref
Crossref
Armin Kalenka & Anke Schwarz. (2009) Anaesthesia and Parkinson's disease: how to manage with new therapies?. Current Opinion in Anaesthesiology 22:3, pages 419-424.
Crossref
Crossref
Xiaohu Zhang, John E. Tellew, Zhiyong Luo, Manisha Moorjani, Emily Lin, Marion C. Lanier, Yongsheng Chen, John P. Williams, John Saunders, Sandra M. Lechner, Stacy Markison, Tanya Joswig, Robert Petroski, Jaime Piercey, William Kargo, Siobhan Malany, Mark Santos, Raymond S. Gross, Jenny Wen, Kayvon Jalali, Zhihong O’Brien, Carol E. Stotz, María I. Crespo, José-Luis Díaz & Deborah H. Slee. (2008)
Lead Optimization of 4-Acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A
2A
Adenosine Receptor Antagonists for the Treatment of Parkinson’s Disease
. Journal of Medicinal Chemistry 51:22, pages 7099-7110.
Crossref
Crossref
John P. Seibyl. (2008) Single-Photon Emission Computed Tomography and Positron Emission Tomography Evaluations of Patients With Central Motor Disorders. Seminars in Nuclear Medicine 38:4, pages 274-286.
Crossref
Crossref
Moisés García-Arencibia, Luca Ferraro, Sergio Tanganelli & Javier Fernández-Ruiz. (2008) Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats. Neuroscience Letters 438:1, pages 10-13.
Crossref
Crossref
Deborah H. Slee, Yongsheng Chen, Xiaohu Zhang, Manisha Moorjani, Marion C. Lanier, Emily Lin, Jaimie K. Rueter, John P. Williams, Sandra M. Lechner, Stacy Markison, Siobhan Malany, Mark Santos, Raymond S. Gross, Kayvon Jalali, Yang Sai, Zhiyang Zuo, Chun Yang, Julio C. Castro-Palomino, María I. Crespo, Maria Prat, Silvia Gual, José-Luis Díaz & John Saunders. (2008)
2-Amino-
N
-pyrimidin-4-ylacetamides as A
2A
Receptor Antagonists: 1. Structure−Activity Relationships and Optimization of Heterocyclic Substituents
. Journal of Medicinal Chemistry 51:6, pages 1719-1729.
Crossref
Crossref
Deborah H. Slee, Xiaohu Zhang, Manisha Moorjani, Emily Lin, Marion C. Lanier, Yongsheng Chen, Jaimie K. Rueter, Sandra M. Lechner, Stacy Markison, Siobhan Malany, Tanya Joswig, Mark Santos, Raymond S. Gross, John P. Williams, Julio C. Castro-Palomino, María I. Crespo, Maria Prat, Silvia Gual, José-Luis Díaz, Jenny Wen, Zhihong O’Brien & John Saunders. (2008)
Identification of Novel, Water-Soluble, 2-Amino-
N
-pyrimidin-4-yl Acetamides as A
2A
Receptor Antagonists with In Vivo Efficacy
. Journal of Medicinal Chemistry 51:3, pages 400-406.
Crossref
Crossref
Alistair Burns, Andrew Yeates, Latif Akintade, Megan del Valle, Richard Y Zhang, Elias M Schwam & Carlos A Perdomo. (2008) Defining Treatment Response to Donepezil in Alzheimer’s Disease. Drugs & Aging 25:8, pages 707-714.
Crossref
Crossref
Amanda L. Sheldon & Michael B. Robinson. (2007) The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochemistry International 51:6-7, pages 333-355.
Crossref
Crossref
John A. Davies. 2007. xPharm: The Comprehensive Pharmacology Reference. xPharm: The Comprehensive Pharmacology Reference
1
3
.
Richard A. Hawkins, Ashwini Mokashi & Ian A. Simpson. (2005) An active transport system in the blood–brain barrier may reduce levodopa availability. Experimental Neurology 195:1, pages 267-271.
Crossref
Crossref
Lothar Lindemann & Marius C. Hoener. (2005) A renaissance in trace amines inspired by a novel GPCR family. Trends in Pharmacological Sciences 26:5, pages 274-281.
Crossref
Crossref
M. ANGELA CENCI & MARTIN LUNDBLAD. 2005. Animal Models of Movement Disorders. Animal Models of Movement Disorders
193
208
.
Karin Stiasny-Kolster, Ralf Kohnen, Erwin Schollmayer, J. Carsten Möller & Wolfgang H. Oertel. (2004) Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: A double-blind, placebo-controlled pilot study. Movement Disorders 19:12, pages 1432-1438.
Crossref
Crossref